{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:33:47Z","timestamp":1780626827358,"version":"3.54.1"},"reference-count":53,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T00:00:00Z","timestamp":1594512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Neuroendocrine tumors (NETs) frequently overexpress somatostatin receptors (SSTR) on their cell surface. The first-line pharmacological treatment for inoperable metastatic functioning well-differentiated NETs are somatostatin analogs. On second line, Lu-DOTA-TATE (177Lu-DOTA0 Tyr 3 octreotate) has shown stabilization of the disease and an increase in progression free survival, as well as effectiveness in controlling symptoms and increasing quality of life. The management of functional NETs before and during LU-DOTA-TATE treatment is specially challenging, as several complications such as severe carcinoid and catecholamine crisis have been described. The aim of this review is to establish practical guidance for the management and prevention of the most common hormonal crises during radionuclide treatment with Lu-DOTA-TATE: carcinoid syndrome (CS) and catecholamine hypersecretion, as well as to provide a brief commentary on other infrequent metabolic complications. To establish a practical approach, a systematic review was performed. This systematic review was developed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and conducted using MEDLINE (accessed from PubMed), Google Scholar and ClinicalTrials.gov. Literature searches found 449 citations, and finally nine were considered for this systematic review.<\/jats:p>","DOI":"10.3390\/jcm9072203","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T11:03:23Z","timestamp":1594724603000},"page":"2203","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Prevention and Management of Hormonal Crisis during Theragnosis with LU-DOTA-TATE in Neuroendocrine Tumors. A Systematic Review and Approach Proposal"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4278-2624","authenticated-orcid":false,"given":"Maria Isabel","family":"del Olmo-Garc\u00eda","sequence":"first","affiliation":[{"name":"Endocrinology and Nutrition Department, University and Polytechnic Hospital La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angustias","family":"Muros","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, University Hospital Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1736-042X","authenticated-orcid":false,"given":"Mart\u00edn","family":"L\u00f3pez-de-la-Torre","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department, University Hospital Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Agudelo","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, University and Polytechnic Hospital La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Bello","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, University and Polytechnic Hospital La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2846-1311","authenticated-orcid":false,"given":"Jose M.","family":"Soriano","sequence":"additional","affiliation":[{"name":"Food &amp; Health Lab, Institute of Materials Science, University of Valencia, 46980 Valencia, Spain"},{"name":"Joint Research Unit on Endocrinology, Nutrition and Clinical Dietetics, University of Valencia-Health Research Institute La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0191-4504","authenticated-orcid":false,"given":"Juan-Francisco","family":"Merino-Torres","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department, University and Polytechnic Hospital La Fe, 46026 Valencia, Spain"},{"name":"Joint Research Unit on Endocrinology, Nutrition and Clinical Dietetics, University of Valencia-Health Research Institute La Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_2","unstructured":"WHO Classification of Tumours Editorial Board (2019). Digestive system tumours. Lyon (France): International agency for research on cancer. WHO Classification of Tumours Series, WHO. [5th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2018-01991","article-title":"Symtomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors","volume":"104","author":"Zandee","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and Paraganglioma","volume":"381","author":"Hartmut","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5603\/NMR.2016.0022","article-title":"Neuroendocrine neoplasms and somatostatin receptor subtypes expression","volume":"19","author":"Jerzy","year":"2016","journal-title":"Nucl. Med. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Remes, S.T., Leijon, L.L., Vesterinen, T.J., Arola, J.J., and Haglund, C.H. (2019). Immunohistochemical Expression of Somatostatin Receptor Subtypes in a Panel of Neuroendocrine Neoplasias. J. Histochem. Cytochem., 1\u201319.","DOI":"10.1369\/0022155419856900"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.beem.2016.01.003","article-title":"Gastroenteropancreatic neuroendocrine tumours (GEP-NET)- Imaging and staging","volume":"30","author":"Baumann","year":"2016","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/MED.0000000000000300","article-title":"Molecular imaging in neuroendocrine tumors: Recent advances, controversies, unresolved issues, and roles in management","volume":"24","author":"Ito","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/14737140.2018.1496822","article-title":"Imaging of pancreatic neuroendocrine tumors: Recent advances, current status, and controversies","volume":"18","author":"Lee","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/MED.0000000000000519","article-title":"Molecular imaging and radionuclide therapy of neuroendocrine tumors","volume":"27","author":"Haider","year":"2020","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2967\/jnumed.117.202275","article-title":"Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors","volume":"59","author":"Hope","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.2967\/jnumed.115.165803","article-title":"68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis","volume":"57","author":"Deppen","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11864-019-0678-6","article-title":"Molecular Imaging and Therapy for Neuroendocrine Tumors","volume":"20","author":"Desai","year":"2019","journal-title":"Curr. Treat Opt. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/er.2017-00062","article-title":"New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification","volume":"38","author":"Crona","year":"2017","journal-title":"Endocr. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-Term Efficacy, Survival, and Safety of [177 Lu-DOTA 0,Tyr 3]octreotate in Patients With Gastroenteropancreatic and Bronchial Neuroendocrine Tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00259-007-0691-z","article-title":"Hormonal crisis following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate","volume":"35","author":"Feelders","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., and Group, P. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_20","unstructured":"National Heart, Lung and Blood Institute (2020, May 06). Quality Assessment Tool for Case Series Studies, Available online: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13139-015-0332-6","article-title":"The Challenges of Treating Paraganglioma Patients With (177)-Lu-DOTATATE PRRT: Catecholamine Crisis, Tumor Lysis Syndrome and the Need of Modification of Treatment Protocols","volume":"49","author":"Makis","year":"2015","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_23","unstructured":"Yadav, S.K., Jha, C.K., Patil, S., Datta, D., Mishra, A., and Pradhan, P.K. (2020). Lutetium therapy-induced carcinoid crisis: A case report and review of literature. J. Can. Res. Ther."},{"key":"ref_24","first-page":"9810194","article-title":"Fatal Systemic Vasoconstriction in a Case of Metastatic Small-Intestinal NET","volume":"2017","author":"Stentzel","year":"2017","journal-title":"Case Rep. Gastrointest. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kolasinska -C\u00b4wik\u0142a, A., Peczkowska, M., Cwik\u0142a, J.B., Micha\u0142owska, I., Pa\u0142ucki, J.M., Bodei, L., Lewczuk-My\u00b4slicka, A., and Januszewicz, A. (2019). A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Mutation. J. Clin. Med., 8.","DOI":"10.3390\/jcm8070952"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.05.003","article-title":"Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions","volume":"66","author":"Li","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ecl.2017.04.004","article-title":"Biochemical Testing in Neuroendocrine Tumors","volume":"46","author":"Aluri","year":"2017","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_29","unstructured":"Nates, J.L., and Price, K.J. (2020). Carcinoid Crisis in the Intensive Care Unit, Springer International Publishing."},{"key":"ref_30","unstructured":"Raedler, L. (2019). Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors. Oncol. Guide FDA Approv. Spec. Feature, 37\u201339."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2214\/AJR.18.19953","article-title":"Neuroendocrine Tumor Therapy: 177Lu-DOTATATE","volume":"211","author":"Mittra","year":"2018","journal-title":"AJR"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2967\/jnumed.118.230607","article-title":"NANETS\/SNMMI Procedure Standard for Somatostatin Receptor\u2013Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE","volume":"60","author":"Hope","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/MED.0000000000000376","article-title":"Carcinoid-syndrome: Recent advances, current status and controversies","volume":"25","author":"Ito","year":"2018","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.5114\/aoms.2016.60311","article-title":"Management of the hormonal syndrome of neuroendocrine tumors","volume":"3","author":"Gut","year":"2017","journal-title":"Arch. Med. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41574-018-0082-5","article-title":"Role of biomarker tests for diagnosis of neuroendocrine tumours","volume":"29","author":"Hofland","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.7314\/APJCP.2014.15.16.6679","article-title":"Somatostatin analogues do not prevent carcinoid crisis","volume":"15","author":"Guo","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"R145","DOI":"10.1530\/ERC-18-0495","article-title":"Management of carcinoid syndrome: A systematic review and meta-analysis","volume":"26","author":"Hofland","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/MPA.0000000000001384","article-title":"Management of Diarrhea in Patients With Carcinoid Syndrome","volume":"48","author":"Naraev","year":"2019","journal-title":"Pancreas"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0039-6060(03)00426-4","article-title":"Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma","volume":"134","author":"Safford","year":"2003","journal-title":"Surgery"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1530\/EJE-07-0778","article-title":"Pheochromocytoma crisis induced by glucocorticoids: A report of four cases and review of the literature","volume":"158","author":"Rosas","year":"2008","journal-title":"Eur. J. Endocrinol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000499497","article-title":"Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma","volume":"109","author":"Mak","year":"2019","journal-title":"Neuroendocrinology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.currproblcancer.2014.01.001","article-title":"Pheochromocytoma and Paraganglioma: Diagnosis, Genetics, Management, and Treatment","volume":"38","author":"Martucci","year":"2014","journal-title":"Curr. Probl. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Mariani-Costantini, R. (2019). Surgical and pharmacological management of functioning pheochromocytoma and paraganglioma. On Paraganglioma: A Multidisciplinary Approach, Codon Publications.","DOI":"10.15586\/paraganglioma.2019"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4103\/0970-1591.194781","article-title":"Current perioperative management of pheochromoytomas","volume":"33","author":"Ramachabdran","year":"2017","journal-title":"Indian J. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/jch.12084","article-title":"Pheochromocytoma\/paraganglioma: Review of perioperative management of blood pressure and update on genetic mutations associated with pheochromocytoma","volume":"15","author":"Fishbein","year":"2013","journal-title":"J. Clin. Hypertens."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Cohen, D., and Fishbein, L. (2018). Hypertension: A companion to Braunwald\u2019s Heart Disease Secondary Hypertension, Elsevier. [1st ed.].","DOI":"10.1016\/B978-0-323-42973-3.00015-9"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1210\/jc.2007-1720","article-title":"Perioperative management of the pheochromocytoma patient","volume":"92","author":"Pacak","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Zaknun","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2020). Diabetes Care in the Hospital: Standards of Medical Care in Diabetes 2020. Diabetes Care, 43, S193\u2013S202.","DOI":"10.2337\/dc20-S015"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2020). Glycemic Targets: Standards of Medical Care in Diabetes 2020. Diabetes Care, 43, S66\u2013S76.","DOI":"10.2337\/dc20-S006"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"(2015). International Hypoglycaemia Study Group. Minimizing Hypoglycemia in Diabetes. Diabetes Care, 38, 1583\u20131591.","DOI":"10.2337\/dc15-0279"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2967\/jnumed.118.217380","article-title":"Tumor Lysis Syndrome: A Rare but Serious Complication of Radioligand Therapies","volume":"60","author":"Huang","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_53","unstructured":"(2020, May 06). Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NETTER-2), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03972488."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/7\/2203\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:50:34Z","timestamp":1760176234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/7\/2203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,12]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["jcm9072203"],"URL":"https:\/\/doi.org\/10.3390\/jcm9072203","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,12]]}}}